GleamWall
中文EN

ZURA Zura Bio Ltd

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1855644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-43.7%
TTM EPS YoY-70.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-65.4%
ROA-55.2%
ROIC (approx.)-164.3%
Asset turnover—

Leverage & solvency

Liabilities / assets8.7%
Debt / equity0.00x
Current ratio11.29x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-42.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$42.08M$24.40M
SG&A expense$33.16M$30.79M
Operating income-$75.25M-$55.19M
Pretax income-$68.65M-$52.40M
Income tax—$0
Net income-$68.65M-$52.40M
EBITDA-$75.20M-$55.18M
EPS (basic)-1.06-0.60
EPS (diluted)-1.06-0.60
Weighted avg. shares (diluted)94.16M75.07M
Balance sheet
Cash & equivalents$109.41M$176,498
Current assets$112.31M$178.74M
PP&E, net$126,000$91,000
Total assets$113.95M$179.53M
Current liabilities$12.41M$19.51M
Total liabilities$12.41M$19.51M
Shareholders' equity$101.54M$146.81M
Shares outstanding73.68M65.30M
Cash flow statement
Operating cash flow-$64.81M-$28.08M
Capital expenditure$113,000$75,000
Free cash flow-$64.93M-$28.15M
Investing cash flow-$113,000-$5.08M
Financing cash flow-$2.16M$109.84M
Depreciation & amortization$49,000$9,000
Stock-based compensation$12.33M$16.80M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.